Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ALXN1210 versus eculizumab in complement inhibitor-naïve adults with PNH
2016-002025-11Phase 3Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Transfusion avoidance. Status: unknown.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2016-002025-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002025-11.